ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report

ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report

Summary

ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

ImmunoGen, Inc. (ImmunoGen or ‘the company’) is a developer of targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology. The ADC technology is comprised of the company's portfolio of cancer-cell killing agents that can be attached to antibodies for targeted delivery to cancer cells. The major partners of the company include Roche, Huadong, CytomX, Debiopharm, Bayer, Novartis, Oxford BioTherapeutics/Menarini, Fusion and Viridian use the company's ADC technology to develop anticancer therapies. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

Scope

• Detailed information on ImmunoGen, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting ImmunoGen, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of ImmunoGen, Inc. including a breakdown and examination of key business segments
• Intelligence on ImmunoGen, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about ImmunoGen, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of ImmunoGen, Inc. and the factors that influence its strategies.
• Track strategic initiatives of the company and latest corporate news and actions.
• Assess ImmunoGen, Inc. as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on ImmunoGen, Inc.'s business structure, strategy and prospects.